Hinge Health, Inc. (HNGE) Operating Margin
- Operating margin · 12 months: Value 13.01%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 13.01% | Operating income / revenue. Period ending 2026-06-30. $93.67M ÷ $720.06M × 100 ≈ 13.01% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 93.67M USD | Operating Income (Loss) |
| Revenue | 720.06M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 129.07M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $93.67M | $720.06M | (m) | $129.07M | (m) | 13.01% |
| 2026-03-31 | $-527.44M | $646.34M | (m) | $374.98M | (m) | -81.60% |
| 2025-12-31 | $-546.37M | $587.86M | (m) | $368.14M | (m) | -92.94% |
| 2025-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $-31.91M | $390.40M | (m) | $100.84M | (m) | -8.17% |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-130.51M | $292.73M | (m) | $110.06M | (m) | -44.59% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.